Will Removal From Russell Value Benchmarks Change Sana Biotechnology's (SANA) Institutional Investor Narrative?
Sana Biotechnology (SANA) was recently removed from several Russell value-oriented benchmarks, including the Russell 2000, which could impact its institutional investor base and liquidity. Despite potential short-term pressure, the article suggests that the company's clinical milestones and funding strategies are more critical for its future. The company faces challenges including significant annual losses, zero revenue, and an ongoing "going concern" warning, with wide-ranging fair value estimates among analysts.
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors - Lead Plaintiff Deadline May 20, 2025
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ:SANA) for alleged securities fraud between March 17, 2023, and November 4, 2024. The lawsuit claims Sana made false statements and concealed risks regarding its financial capacity and the prospects of certain product candidates, leading to shareholder losses. Investors who suffered losses are encouraged to contact Levi & Korsinsky to learn about their rights to recovery, with a lead plaintiff deadline of May 20, 2025.
Sana to show first-in-human islet transplant data without immunosuppression
Sana Biotechnology (NASDAQ: SANA) is set to present clinical data on UP421, an allogeneic primary islet cell therapy utilizing its hypoimmune platform, at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. This first-in-human transplant data for type 1 diabetes will highlight the potential for treatment without immunosuppression. The presentation is scheduled for October 2, 2026, in Milan, Italy.
Sana Biotechnology Announces Symposium Presentation at the
Sana Biotechnology, Inc. (NASDAQ: SANA) announced a symposium presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The presentation will highlight clinical data from a first-in-human study of UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune platform technology, in a patient with type 1 diabetes without immunosuppression. The symposium is scheduled for October 2, 2026, in Milan, Italy.
Citizens reiterates Sana Biotechnology stock rating on IND filing
Citizens has reiterated a Market Outperform rating and an $8.00 price target for Sana Biotechnology (NASDAQ:SANA) following the company's plans to file an Investigational New Drug application for SG293, their first fusogen-based in vivo CAR-T program. Although the stock currently trades above its Fair Value, Wall Street analysts maintain an optimistic consensus price target range of $7 to $12. Preclinical data for SG293 showed promising results in non-human primates, supporting its advancement toward human trials, despite the company reporting a Q1 loss and the stock's high volatility.
Will Removal From Russell Value Benchmarks Change Sana Biotechnology's (SANA) Institutional Investor Narrative?
Sana Biotechnology (SANA) was recently removed from several Russell value benchmarks, which could impact its institutional investor base and liquidity. The article emphasizes that while this removal might affect passive ownership and increase volatility, the company's core scientific advancements and funding milestones remain more crucial for its long-term investment narrative. Investors are also cautioned about the company's significant annual losses, zero revenue, and ongoing "going concern" warning.
Will Removal From Russell Value Benchmarks Change Sana Biotechnology's (SANA) Institutional Investor Narrative?
Sana Biotechnology (SANA) was recently removed from several Russell value benchmarks, which could impact its institutional investor base and liquidity. The company faces significant financial challenges, including annual losses and zero revenue, with its future largely dependent on clinical trial success and securing further funding. While the immediate share price reaction was modest, longer-term reduced passive ownership might amplify stock volatility around setbacks, making the "going concern" warning a critical issue for investors.
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 3000 Value Benchmark
Sana Biotechnology, Inc. (NasdaqGS: SANA) has been removed from the Russell 3000 Value Benchmark. This news follows several other index removals for the company, including the Russell Small Cap Comp Value Benchmark, Russell 2500 Value Benchmark, and Russell 2000 Value Benchmark. The biotechnology company is focused on developing engineered cell therapies for various therapeutic areas.
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 2500 Value Benchmark
Sana Biotechnology, Inc. (NasdaqGS: SANA) has been removed from the Russell 2500 Value Benchmark. This news comes amidst several other recent announcements regarding the company's removal from various Russell indices and presentations at healthcare conferences, as well as an equity offering and preclinical data presentation. Analysts currently rate Sana Biotechnology with a "BUY" consensus and an average target price of $8.571 USD, significantly higher than its last closing price of $3.490 USD.
Join Class Action to Recover Losses from Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) seeking to recover losses for shareholders who purchased shares between March 17, 2023, and November 4, 2024. The lawsuit alleges that Sana Biotechnology made false statements regarding its financial capacity and the prospects of certain product candidates (SC291, SC379, and SG299). Shareholders who sustained losses during this period are encouraged to contact Levi & Korsinsky for information on their rights before May 20, 2025.
Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025
Levi & Korsinsky LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) for alleged securities fraud between March 17, 2023, and November 4, 2024. The lawsuit claims Sana overstated its financial capacity and the prospects of certain product candidates, leading to investor losses. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky to learn about their rights to recovery before May 20, 2025.
Price to earnings forward of Sana Biotechnology, Inc. – NASDAQ:SANA
This page from TradingView displays financial information for Sana Biotechnology, Inc. (NASDAQ: SANA), specifically focusing on its price-to-earnings forward metric. The content indicates that the company's market data is closed with no trades. The article is a financial data page rather than a traditional news article.
Enterprise value to EBIT forward of Sana Biotechnology, Inc. – NASDAQ:SANA
This article provides the enterprise value to EBIT forward for Sana Biotechnology, Inc. (NASDAQ: SANA). It presents financial data via TradingView, indicating no current trades and a closed market for the stock. The content primarily focuses on the financial metric for SANA.
Sana Biotechnology, Inc. Actuals & Estimates (NASDAQ:SANA)
This article provides an overview of Sana Biotechnology, Inc. (NASDAQ:SANA)'s financial actuals and estimates. It covers the current stock price, historical highs and lows, market capitalization, earnings reports, revenue, net income, and analyst forecasts for future price targets. The company's next earnings report is scheduled for July 30, 2026.
SANA Forecast — Price Target — Prediction for 2027
The article provides a forecast for Sana Biotechnology, Inc. (SANA) stock, including current price, analyst ratings, and historical performance. Analysts project a max estimate of $16.00 and a min estimate of $7.00 for SANA, with a current price of $3.26. The company's financials, earnings, and volatility are also detailed, along with upcoming earnings report dates.
Sana Biotechnology Inc (SANA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Sana Biotechnology Inc's (SANA) dividends and stock splits. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stock prices and market capitalization for SANA.
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Sana Biotechnology Inc (SANA), including analyst ratings, price targets, and EPS estimates. Based on 9 analysts, the stock has a "Buy" rating with a target price of $7.00, representing a significant upside. The report also highlights past EPS performance and future expectations.
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.14, Implies 230% Upside
Sana Biotechnology, Inc.'s average 12-month price target has been lowered from $9.50 to $9.14 by 7 analysts, with individual forecasts ranging from $7 to $16 per share. This updated target suggests a potential upside of approximately 230% from its Jun. 11 closing price. Despite the price target cut, the consensus rating from 9 analysts remains a "Buy," with 8 expressing a Buy and 1 a Hold.
Sana Biotechnology raises $69M through ATM share sale
Sana Biotechnology has raised $69 million through an "at-the-market" (ATM) share offering. The company sold 8.6 million shares at an average price of $8.07 per share. This capital raise was executed through an amendment to a prior sales agreement with Cowen and Company and SVB Securities.
SANA SEC Filings - Sana Biotechnology, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Sana Biotechnology, Inc. (SANA) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. Recent disclosures cover executive changes, financial results with asset write-downs, capital raises, and positive clinical trial updates for UP421. The platform tracks 49 filings, offering AI-generated summaries, impact scoring, and sentiment analysis for investors.
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bilenker Joshua H.
This article is a statement of changes in beneficial ownership of securities for Sana Biotechnology, specifically concerning Director Joshua H. Bilenker. This indicates a transaction related to his holdings in the company.
Sana Biotechnology (SANA) director granted 90,000 stock options at $2.96 strike
Sana Biotechnology director Robert L. Rosiello was granted 90,000 stock options with an exercise price of $2.96 per share, expiring on June 3, 2036. The options will fully vest on the earlier of June 4, 2027, or just before Sana's 2027 annual shareholder meeting, provided Rosiello maintains continuous service. This is a compensation award, not an open-market purchase, and is detailed in a Form 4 SEC filing.
Sana Biotechnology (SANA) director granted 90,000 stock options at $2.96 strike
Sana Biotechnology director Alise Reicin was granted 90,000 stock options with an exercise price of $2.96 per share, expiring on June 3, 2036. These options vest 100% on the earlier of June 4, 2027, or immediately before the 2027 annual stockholder meeting, provided continuous service. This grant is considered a routine equity compensation event aimed at retention rather than a market trading signal.
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director NELSEN ROBERT
This document is a Form 4 statement from Sana Biotechnology, detailing changes in beneficial ownership of securities for Director NELSEN ROBERT. It serves as an official report of transactions involving company stock by an insider.
Sana Biotechnology (SANA) director receives 90,000-share stock option grant
Sana Biotechnology (SANA) director Hans Edgar Bishop was granted stock options for 90,000 shares of Common Stock with an exercise price of $2.96 per share. Following this grant, he directly holds options on 90,000 shares. The options are set to vest on the earlier of June 4, 2027, or immediately before the company's 2027 annual stockholders meeting, contingent on his continued service to Sana.
Director Michelle Seitz gets 90,000 Sana (SANA) stock options
Sana Biotechnology director Michelle Seitz was granted 90,000 stock options with an exercise price of $2.96 per share, expiring on June 3, 2036. These options will vest on the earlier of June 4, 2027, or immediately before the company's 2027 annual stockholder meeting, contingent on her continued service. This award is a compensation-related acquisition, not an open-market purchase, increasing her direct holdings to 90,000 stock options.
Sana Biotechnology (SANA) director granted 90,000 stock options at $2.96
Sana Biotechnology, Inc. director Joshua H. Bilenker was granted 90,000 stock options with an exercise price of $2.96 per share, expiring on June 3, 2036. These options vest fully on the earlier of June 4, 2027, or immediately before Sana's 2027 annual meeting, contingent on his continuous service. Following this grant, Bilenker directly holds 90,000 derivative securities.
Sana Biotechnology (SANA) director awarded options for 90,000 shares at $2.96
Sana Biotechnology director Patrick Y. Yang has been granted stock options for 90,000 shares of common stock at an exercise price of $2.96 per share. These options will vest completely on the earlier of June 4, 2027, or just before the company's 2027 annual stockholder meeting, contingent on his continuous service. Following this grant, Yang now holds 90,000 derivative securities related to Sana Biotechnology common stock.
Sana (SANA) director awarded 90,000 stock options vesting in 2027
Sana Biotechnology director Robert Nelsen was granted 90,000 stock options with an exercise price of $2.96 per share, expiring on June 3, 2036. These options will vest 100% on the earlier of June 4, 2027, or immediately before Sana's 2027 annual stockholder meeting, contingent on continuous service. This transaction is a compensation award and not a market purchase or sale of shares.
Sana Biotechnology (SANA) shareholders elect directors, ratify Ernst & Young LLP
Sana Biotechnology, Inc. (SANA) announced the results of its 2026 annual meeting, where shareholders elected three Class II directors—Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.—to three-year terms. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The filing provides detailed vote counts for each proposal and director nominee, including votes for, withheld, and broker non-votes.
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Sana Biotechnology, Inc. (NASDAQ: SANA) breached their fiduciary duties to shareholders. The firm encourages long-term Sana shareholders to contact them to discuss potential legal rights and options, including seeking corporate governance reforms or financial incentives. Halper Sadeh LLC emphasizes that shareholder involvement can improve company policies and enhance shareholder value.
Sana Biotechnology (SANA) grants director 90,000 stock options at $2.96
Sana Biotechnology's director, Richard Mulligan, has been granted 90,000 stock options with an exercise price of $2.96 per share, expiring on June 3, 2036. The options will vest 100% on the earlier of June 4, 2027, or immediately before the company's 2027 annual stockholders’ meeting, provided he continues his service. This transaction was reported via a Form 4 filing accepted by the SEC on June 5, 2026.
Law firm probes Sana Biotech officers for possible shareholder duty breaches
Halper Sadeh LLC is investigating whether officers and directors of Sana Biotechnology, Inc. (SANA) have breached their fiduciary duties to shareholders. The law firm offers free consultations and works on a contingency fee basis. This investigation could result in corporate governance reforms or financial compensation for long-term Sana shareholders if misconduct is discovered.
SANA - Sana Biotechnology Inc Stock Price and Quote
This article provides comprehensive financial data, news, and analyst ratings for Sana Biotechnology Inc. (SANA). It covers the company's stock performance, key financial metrics, insider transactions, and a timeline of recent news and analyst actions, including investment bank ratings and price target changes.
Sana Biotechnology to Present at June 2026 Investor Conferences
Sana Biotechnology, Inc. (NASDAQ: SANA) announced it will present at two investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th. The presentations will offer a business overview and update, with webcasts accessible on Sana's investor relations page. The company focuses on developing engineered cell therapies and has operations in Seattle, Cambridge, and South San Francisco.
Sana Biotechnology to Present at June 2026 Investor Conferences
Sana Biotechnology, Inc. announced its participation in two investor conferences in June 2026. The company will present at the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th, providing a business overview and update. Webcasts of these presentations will be available on Sana's investor relations website.
Sana Biotechnology to Present at June 2026 Investor Conferences
Sana Biotechnology, Inc. (NASDAQ: SANA) announced it will present at two investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th. The presentations will offer a business overview and update, with webcasts available on the company's investor relations page. Sana Biotechnology is focused on developing engineered cells as medicines.
Stream Sana Biotechnology's June investor talks live online
Sana Biotechnology (NASDAQ: SANA) will present at two investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. The company will provide a business overview and corporate update at both events. Live webcasts and 30-day replays will be available on Sana's investor relations website.
Sana Biotechnology to Present at June 2026 Investor Conferences
Sana Biotechnology, Inc. (NASDAQ: SANA) announced it will present at two investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th. Both presentations will provide a business overview and update, with webcasts accessible on the company's Investor Relations page. The company focuses on developing engineered cell therapies.
Sana Biotechnology to Present at June 2026 Investor Conferences
Sana Biotechnology, Inc. (NASDAQ: SANA) announced it will present at two investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th. The presentations will offer a business overview and update, with webcasts accessible on Sana's investor relations website. The company focuses on engineered cells as medicines and operates in Seattle, Cambridge, and South San Francisco.
RA Capital affiliates report 18.75M Sana Biotechnology shares (NASDAQ: SANA)
RA Capital Management and its affiliated entities have reported a beneficial ownership of 18,750,000 shares of Sana Biotechnology (NASDAQ: SANA) common stock, representing 6.3% of the class. This disclosure was made in a Schedule 13G filing, indicating a passive investment. The percentage calculation is based on 278,291,590 outstanding shares as of April 30, 2026, plus an additional 21,607,878 shares issued through an at-the-market offering by May 14, 2026.
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
Sana Biotechnology, Inc. has sold approximately $69 million worth of common stock through its at-the-market (ATM) facility, extending its cash runway to mid-2027. This includes a $25 million investment from the Mayo Clinic, bringing total capital raised since Q1 2026 to about $94 million. The company aims to develop engineered cells as medicines.
InvestingPro Fair Value spotted Sana Biotech overvaluation early By Investing.com
InvestingPro's Fair Value analysis accurately identified Sana Biotechnology (NASDAQ:SANA) as overvalued in December 2025, predicting a significant price drop. The stock subsequently fell 40%, validating the model's assessment which uses multiple valuation methodologies to determine intrinsic value. Even after the decline, InvestingPro suggests Sana Bio remains overvalued, highlighting its financial weaknesses and dependence on capital raises.
Sana Biotechnology raises $69M through ATM share sale
Sana Biotechnology has successfully raised $69 million through an "at-the-market" (ATM) offering of its common stock. The company sold 8.6 million shares at an average price of $8.01 per share under a sales agreement established in November 2023. This capital infusion will support the company's operations and ongoing research and development efforts.
Sana Biotechnology Raises $69 Million Through ATM Equity Offering
Sana Biotechnology has successfully completed an "at-the-market" (ATM) equity offering, raising approximately $69 million in gross proceeds. This financial move involved selling 8,943,285 shares of its common stock through an existing sales agreement. The additional capital is expected to support the company's ongoing operations and development pipeline.
Sana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market Facility
Sana Biotechnology (SANA) stock declined significantly after the company announced it had sold 10.9 million shares through an "at-the-market" facility, raising approximately $69.1 million. This sale, conducted via Cowen and Company, priced the shares at an average of $6.34 each. Despite the capital raise, the increased share count due to the offering negatively impacted investor sentiment.
Sana Biotechnology | 8-K: Current report
Sana Biotechnology completed a common stock offering on May 15, 2026, selling 21,607,878 shares for net proceeds of approximately $69.0 million. This capital raise, executed via an at-the-market offering with TD Securities (USA) LLC, provides additional funding for the company's operations and development programs while minimizing shareholder dilution.
Sana Biotechnology (SANA) sells 21.6M shares to raise about $69M
Sana Biotechnology, Inc. announced it sold 21.6 million shares of common stock, generating approximately $69 million in net proceeds. These shares were sold through an amended and restated sales agreement with TD Securities (USA) LLC, which served as the sales agent. The transaction provides the company with additional capital and increases its share count.
Sana Biotechnology Raises $69 Million Through Equity Offering
Sana Biotechnology (SANA) recently raised approximately $69 million by selling 21.6 million common shares through an equity offering with TD Securities (USA) LLC. This capital injection is intended to bolster the company's financial position, supporting its ongoing operations and strategic growth plans in the competitive biotechnology sector. Despite the strengthened funding outlook, TipRanks' AI Analyst "Spark" rates SANA as "Neutral" due to weak financial performance and technical price trends, partially offset by recent strategic investments and financing flexibility.
Sana Biotechnology, Inc. (SANA) Leadership & Management Team Analysis
This article provides an analysis of Sana Biotechnology, Inc.'s leadership and management team, including CEO Steve Harr's compensation, tenure, and ownership. It summarizes recent management updates, key risks such as cash runway and share price volatility, and updates on their clinical programs for type 1 diabetes and autoimmune diseases. The company is actively focusing on its immuno-engineering platforms and exploring partnerships to advance its product candidates.
